Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.62 |
| ▸ | TNFRSF1A | P19438 | 4/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | TUBB1 | Q9H4B7 | 6/20 | 0.56 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.54 |
| ▸ | TUBB | P07437 | 3/20 | 0.54 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.54 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.54 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.54 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.54 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.54 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.54 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.54 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.54 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.54 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL805335 | 1.00 | MAPT (0.69) | MAPTLMNAABCG2TNFRSF1AABCB1 | |
| SCHEMBL24253122 | 0.87 | MAPT (0.58) | MAPTLMNAABCG2TNFRSF1AABCB1 | |
| SCHEMBL1446863 | 0.86 | MAPT (0.57) | MAPTLMNAABCG2TNFRSF1AABCB1 | |
| SCHEMBL1446864 | 0.86 | MAPT (0.57) | MAPTLMNAABCG2TNFRSF1AABCB1 | |
| SCHEMBL801293 | 0.83 | MAPT (0.64) | MAPTLMNAABCG2TNFRSF1AABCB1 | |
| SCHEMBL805341 | 0.82 | MAPT (1.00) | MAPTLMNAABCG2TNFRSF1AABCB1 | |
| SCHEMBL783250 | 0.82 | MAPT (1.00) | MAPTLMNAABCG2TNFRSF1AABCB1 | |
| SCHEMBL11539495 | 0.81 | ABCG2 (0.68) | ABCG2TNFRSF1AABCB1TUBB1TUBB4A | |
| SCHEMBL15777949 | 0.80 | MAPT (0.78) | MAPTLMNAABCG2TNFRSF1AABCB1 | |
| SCHEMBL801281 | 0.80 | MAPT (0.78) | MAPTLMNAABCG2TNFRSF1AABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2959898-A1 | 4,5-DIOXO-NAPHTHO[1,2-b]FURANS AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | Sloan-Kettering Institute for Cancer Research (US) | 2015-12-30 | — | — | EP | disclosed |
| EP-2427057-B1 | BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | SLOAN KETTERING INST CANCER (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8614237-B2 | Benzofuran-4,5-diones as selective peptide deformylase inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2013-12-24 | — | — | US | disclosed |
| US-20120071523-A1 | BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-03-22 | — | — | US | disclosed |
| EP-0862560-B1 | SUBSTITUTED 2-ANILINOPYRIMIDINES USEFUL AS PROTEIN KINASE INHIBITORS | CELLTECH THERAPEUTICS LTD (GB) | 2003-04-02 | — | — | EP | disclosed |
| US-6235746-B1 | AUTOIMMUNE DISEASES; ANTIPROLIFERATIVE AGENT | CELLTECH THERAPEUTICS, LIMITED (GB) | 2001-05-22 | — | — | US | disclosed |
| US-5958935-A | Substituted 2-anilinopyrimidines useful as protein kinase inhibitors | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-09-28 | — | — | US | disclosed |
| US-5612340-A | ANTITUMOR AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-03-18 | — | — | US | disclosed |
| EP-0672035-A1 | PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995009847-A1 | PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | CIBA-GEIGY AG (CH) | 1995-04-13 | — | — | WO | disclosed |
| US-4175087-A | ENAMINOKETONES WITH ALKYLLITHIUM | ELI LILLY AND COMPANY (US) | 1979-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071523-A1 | BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | PDF, EIF5B, EIF4E | MAPT 3128/4885LMNA 3542/4885ABCG2 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.